|
Understanding Intellectual Property in Generative AI: Navigating Innovation,
Rights and Challenges Across Law, Technology and Pharmahosted by the New Jersey Chapter
Thursday, September 28, 20235:30pm - 8:30pm Eastern
at
Basking Ridge Country Club
185 Madisonville Road
Basking Ridge, NJ 07920
 Program:
Discover how Generative AI is transforming law, technology, and pharmaceuticals, and gain a comprehensive understanding of the intellectual property rights and challenges associated with this cutting-edge technology. Our esteemed panel of experts will share their expertise on topics such as copyright, patents, and data protection in the context of Generative AI applications. Examining real-world case studies and best practices in IP management for AI-driven innovation Speakers: 
| Mike Kasdan, Partner, Wiggin and Dana, LLP
Mike Kasdan, a Partner at Wiggin and Dana LLP, specializes in intellectual property (IP) and heads its Blockchain, Digital Assets, and Trade Secret groups. He works with clients from varied industries, including fintech, consumer electronics, and entertainment, providing litigation, licensing, and counseling on IP strategy. Kasdan is deeply involved in the emerging Web3 and AI spaces, offering guidance on digital asset licensing and commercialization, as well as IP strategy.
As a thought leader in AI, Kasdan shares his insights through speaking engagements, writing, and interviews with various outlets such as Variety Magazine. His article on the challenges posed to copyright law by AI was selected as the May 2023 "Article of the Month" by The Licensing Executives Society International.
Apart from his law practice, Kasdan teaches IP licensing as an Adjunct Professor at the NYU School of Law and guest lectures at the NYU Law Business Clinic and NYU Entrepreneurship Institute.
Recognized as a leading IP strategist and listed in Super Lawyers, Kasdan also advocates for diversity, social justice, and mental health. He is the founder of Lawyering While Human, Director of Special Projects for The Good Men Project, and co-host of The Inclusion Evolution Podcast. |  |
Phil Crowley, Managing Partner, Crowley Law, LLC
Phil Crowley is managing partner of Crowley Law LLC, a boutique law firm focused on the needs of life sciences and other technology companies. Prior to founding Crowley Law in 2015, Phil served as Assistant General Counsel for Johnson & Johnson. Prior to joining Johson & Johnson in 1982, he was a corporate associate at Cravath, Swaine & Moore in NYC focused on mergers and acquisitions and bank and securities financings. He serves as a member of the Board of Trustees of Stevens Institute of Technology in Hoboken and is a member of the Board of Directors of Ben Franklin Technology Partners of Northeast Pennsylvania. He is the Chairman of the NJ State Bar Association Venture Capital, Angel Investor and Startup Law Committee. The firm is a member of Bio NJ, New York BIO and Bio Florida. Phil holds a B.S. in physics from Stevens, an M.S. in experimental physics from Harvard University and a J.D. from Columbia Law School. | 
| Brendan Englot, PhD, Director, Stevens Institute for Artificial Intelligence (SAI)
Dr. Englot serves as the Director of the Stevens Institute for Artificial Intelligence (SIAI) at Stevens Institute of Technology, where he is also an Associate Professor of Mechanical Engineering, and holds the Geoffrey S. Inman Professorship. Brendan has fifteen years of experience developing and deploying mobile robots and autonomous navigation algorithms via land, air and sea. His research uses artificial intelligence to improve the situational awareness of mobile robots operating in degraded conditions, and to enable intelligent robot decision-making under uncertainty. His work in A.I. is supported by the National Science Foundation, the Office of Naval Research, the U.S. Army, and various sponsors in industry.
| 
| Elizabeth Farley, Co-Founder, Chief Operating and Data Officer, Talking Medicines Elizabeth Fairley is a co-founder and Chief Operating and Data Officer at Talking Medicines Limited. Her expertise lies in leveraging data to empower advertizing agencies and marketing departments in the pharmaceutical sector with actionable insights from data acquired from the internet. The Talking Medicines approach is to use advanced data science and an artificial intelligence engine to find “the needle in the haystack”, i.e. the true voices of patients, healthcare providers and key opinionleaders – and importantly, to analyze that “needle” to provide actionable information. Elizabeth earned an MBA at Babson College Business School (Saltire Fellow), holds a Ph.D. in Biology from the University of Cambridge, and a BSc (Hons) in Genetics from the University of Aberdeen. As an entrepreneur, Elizabeth has founded various successful enterprises, including her own life sciences consultancy business. | 
| Sunil Paliwal, Teaching Associate, Stevens Institute of Technology
He has 15 years experience as a medicinal chemist and project leader performing research in drug discovery for Schering-Plough Research Institute and at Merck where he was Director of Exploratory Medicinal Chemistry. His expertise is in developing small molecules to treat oncology, neurological, cardiovascular and inflammation diseases.
Dr. Paliwal’s preclinical discovery includes leading teams to discover early drug hits from high-throughput screening (HTS) involving the screening of millions of compounds, optimization of hits and developing program leads through evaluations of chemical structure and biological data to develop key structural-activity-relationships (SAR). Dr. Paliwal’s research experience also include optimization of the DMPK and biological data of the leads to deliver clinical compounds with optimal DMPK/pharmacological properties. He is co-inventor of a drug (Varubi®) and has progressed two other compounds into clinic to treat cancer and neurological diseases.
| 
| Pin-Kuang Lai, PhD, Assistant Professor, Stevens Institute of Technology Dr. Lai, is Assistant Professor at Stevens Institute of Technology. His research is dedicated to tackling the challenges of drug design and development by using machine learning, molecular simulations and high-throughput screening. In particular, our lab focuses on antimicrobial peptides (AMPs) and antibodies. He has a PhD on Chemical Engineering from University of Minnesota and has experience in molecular engineering and mechanism
study for biological system. | 
| Paul Jeffrey, Founder, PJ BioPharma Solutions, LLC Founder of PJ BioPharma Solutions, LLC, a company dedicated of providing customized business and BD solutions for biotech startups and pharma companies, small and large. He has 40+ years of pharma and biotech experience with my extensive and vast pharma network to provide customized services Full Spectrum of Advisory Services, and Strategic New Product Development. |
Cost: includes heavy appetizers, desserts, coffee, tea, non-alcoholic drinks, beer and wine.
| | Member | Non-Member
| Early Bird (extended through September 27!)
| $65 | $75 | Regular
| $75 | $85 |
Thank you to our Sponsors:
|  | PJ BioPharma Solutions, LLC |
Email Consent: By registering for this event, you permit LES to use your email address to communicate with you regarding LES events and their other services. You will have the ability to unsubscribe from these communications going forward.
|
Print Page
